RaQualia Pharma Inc. (TYO:4579)
725.00
-18.00 (-2.42%)
Nov 18, 2026, 10:14 AM JST
RaQualia Pharma Revenue
RaQualia Pharma had revenue of 895.00M JPY in the quarter ending September 30, 2026, with 15.48% growth. This brings the company's total for the last twelve months to 4.02B, up 31.77% year-over-year. In the year 2025, RaQualia Pharma had annual revenue of 3.98B with 28.07% growth. That makes RaQualia Pharma the 32,490th largest company in the world by revenue and 3,401st in Japan.
Revenue (ttm)
4.02B
Revenue Growth
+31.77%
P/S Ratio
4.81
Revenue / Employee
47.27M
Employees
85
Market Cap
18.87B
Revenue by Geography
- Asia 2.05B 51.5%
- Japan 1.07B 26.8%
- United States of America 861.00M 21.6%
Fiscal year ended Dec 31, 2025 See the full RaQualia Pharma breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.98B | 872.00M | 28.07% |
| Dec 31, 2024 | 3.11B | 1.21B | 63.44% |
| Dec 31, 2023 | 1.90B | -1.02B | -34.85% |
| Dec 31, 2022 | 2.92B | 142.00M | 5.12% |
| Dec 31, 2021 | 2.78B | 1.67B | 150.77% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2014 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Kidswell Bio | 6.14B |
| Japan Tissue Engineering | 2.68B |
| ReproCELL | 2.30B |
| Immuno-Biological Laboratories | 1.08B |
| AnGes | 962.00M |
| Stella Pharma | 323.00M |
| Healios K.K. | 59.00M |
| Kubota Pharmaceutical Holdings | 16.00M |